Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

149.23
Delayed Data
As of Sep 03
 -3.06 / -2.01%
Today’s Change
127.67
Today|||52-Week Range
181.81
-6.32%
Year-to-Date
Build a Core Position in Biotech Intrexon at These Lower Prices
Sep 03 / TheStreet.com
A Word of Advice for Amgen: Objects in the Mirror Are Closer Than They Appear
Aug 31 / MotleyFool.com
3 Stocks Pushing The Drugs Industry Lower
Sep 03 / TheStreet.com
Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor
Aug 31 / Zacks.com
Amgen (AMGN) Stock Falls as Novartis Begins Selling Biosimilar Version of Neupogen
Sep 03 / TheStreet.com
Smith & Wesson powers ahead on strong sales
Aug 28 / FT.com
Novartis launches first biological copycat drug in US
Sep 03 / FT.com
Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.
Aug 28 / Zacks.com
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S.
Sep 03 / Zacks.com
Frontrunning: August 28
Aug 28 / Investing Channel
The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam
Sep 03 / Zacks.com
Time to Buy Amgen After Newly Approved Drug?
Aug 28 / TheStreet.com
Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Sep 02 / Zacks.com
Aug. 28 Premarket Briefing: 10 Things You Should Know
Aug 28 / TheStreet.com
Regeneron and Sanofi Present Encouraging Praluent Data
Sep 02 / Zacks.com
The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macro...
Aug 27 / Zacks.com
AstraZeneca Strikes Deal with Valeant for Psoriasis Drug
Sep 02 / Zacks.com
You Can't Keep Volatility Down Forever
Aug 26 / TheStreet.com
Amgen Inc.'s FDA Approval Holds Blockbuster Potential
Sep 02 / MotleyFool.com
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Aug 26 / Zacks.com
Morning Buzz : Ambarella (AMBA), Vera Bradley (VRA), Navistar (NAV), BiondVax (BVXV),...
Sep 02 / Investing Channel
US 'big four' biotechs lead sector tumble into bear market
Aug 24 / FT.com
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target?
Sep 02 / Zacks.com
Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday
Aug 21 / Zacks.com
Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern
Sep 02 / MotleyFool.com
This Is a Concern That Amgen Investors Shouldn't Take Lightly
Aug 20 / MotleyFool.com
Sept. 2 Premarket Briefing: 10 Things You Should Know
Sep 02 / TheStreet.com
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Aug 19 / Zacks.com
Rigor Mortis Of The Robo-Machines
Sep 01 / Investing Channel